Accelerate Diagnostics, Inc. (AXDX)
Stock Price:
$14.68 USD
-0.16 (-1.08%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
827.29M |
| Revenue (ttm) |
10.21M |
| Net Income (ttm) |
-82.31M |
| Shares Out |
56.36M |
| EPS (ttm) |
-1.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$14.68 |
| Previous Close |
$14.84 |
| Change ($) |
-0.16 |
| Change (%) |
-1.08% |
| Day's Open |
15.06 |
| Day's Range |
14.09 - 15.49 |
| Day's Volume |
228,702 |
| 52-Week Range |
4.53 - 22.13 |
More Stats
| Market Cap |
827.29M |
| Enterprise Value |
882.67M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.36M |
| Float |
26.55M |
| EPS (basic) |
-1.5 |
| EPS (diluted) |
-1.50 |
| FCF / Share |
-1.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
17.30M |
| Short Ratio |
34.92 |
| Short % of Float |
49.63% |
| Beta |
2.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
81.04 |
| PB Ratio |
n/a |
| Revenue |
10.21M |
| Operating Income |
-69.38M |
| Net Income |
-82.31M |
| Free Cash Flow |
-59.52M |
| Net Cash |
-55.38M |
| Net Cash / Share |
-0.98 |
| Gross Margin |
43.10% |
| Operating Margin |
-679.65% |
| Profit Margin |
-806.30% |
| FCF Margin |
-583.11% |
| ROA |
-31.71% |
| ROE |
-837.84% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$16.67*
(13.56% upside)
Low
12.0
Current: $14.68
High
20.0
Target: 16.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 9.30 | 5.67 | 4.18 | 0.25 | 0.15 | 0.12 | 0.05 | 0.24 | 1.12 | 2.25 |
| Revenue Growth | 63.97% | 35.74% | 1597.97% | 67.35% | 20.49% | 154.17% | -79.66% | -78.95% | -50.07% | - |
| Gross Profit | 4.40 | 2.48 | 3.18 | 0.25 | 0.15 | 0.12 | 0.05 | 0.24 | 1.12 | 2.25 |
| Operating Income | -72.83 | -80.37 | -64.18 | -66.50 | -45.55 | -30.99 | -15.31 | -5.35 | -0.41 | 0.61 |
| Net Income | -84.31 | -88.33 | -64.03 | -66.37 | -45.50 | -30.93 | -15.28 | -5.31 | -0.38 | 0.64 |
| Shares Outstanding | 54.51 | 54.49 | 54.07 | 51.28 | 45.00 | 43.63 | 37.60 | 12.46 | 10.79 | 10.41 |
| Earnings Per Share | -1.55 | -1.62 | -1.18 | -1.29 | -1.01 | -0.71 | -0.41 | -0.43 | -0.04 | 0.06 |
| Operating Cash Flow | -64.79 | -67.76 | -55.75 | -53.41 | -35.13 | -18.79 | -9.75 | -0.82 | 0.45 | -0.79 |
| Capital Expenditures | -0.33 | -1.00 | -2.97 | -2.41 | -3.66 | -1.93 | -1.16 | -0.10 | -0.08 | -0.05 |
| Free Cash Flow | -65.12 | -68.75 | -58.71 | -55.82 | -38.78 | -20.72 | -10.91 | -0.91 | 0.37 | -0.84 |
| Cash & Equivalents | 108 | 166 | 109 | 77.76 | 132 | 66.68 | 41.99 | 14.26 | 0.78 | 0.28 |
| Total Debt | 134 | 120 | - | - | 0.01 | 0.16 | - | - | - | - |
| Net Cash / Debt | -25.62 | 46.40 | 109 | 77.76 | 132 | 66.52 | 41.99 | 14.26 | 0.78 | 0.28 |
| Assets | 134 | 185 | 126 | 82.85 | 139 | 69.80 | 43.43 | 17.21 | 6.26 | 6.27 |
| Liabilities | 142 | 128 | 6.81 | 5.04 | 6.31 | 3.81 | 1.91 | 2.38 | 1.45 | 1.36 |
| Book Value | -7.38 | 57.38 | 119 | 77.82 | 133 | 65.99 | 41.52 | 14.84 | 4.82 | 4.91 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Accelerate Diagnostics, Inc. |
| Country |
United States |
| Employees |
275 |
| CEO |
Jack Phillips |
Stock Information
| Ticker Symbol |
AXDX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: AXDX |
| IPO Date |
November 18, 1996 |
Description
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.